Product nameAnti-eIF4G1 antibody
See all eIF4G1 primary antibodies
DescriptionRabbit polyclonal to eIF4G1
Tested applicationsSuitable for: WB, IP, IHC-Pmore details
Species reactivityReacts with: Human
Synthetic peptide within Human eIF4G1 aa 525-575. The exact sequence is proprietary. NP_886553.2.
Database link: Q04637
- IHC-P: Human ovarian carcinoma tissue. WB: HeLa whole cell lysate. IP: HeLa whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: Tris buffered saline, 0.1% BSA
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab264233 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 175 kDa.|
|IP||Use at 2-5 µg/mg of lysate.|
|IHC-P||1/100 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionComponent of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome.
Involvement in diseaseDefects in EIF4G1 are the cause of Parkinson disease type 18 (PARK18) [MIM:614251]. An autosomal dominant, late-onset form of Parkinson disease. Parkinson disease is a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.
Sequence similaritiesBelongs to the eIF4G family.
Contains 1 MI domain.
Contains 1 MIF4G domain.
Contains 1 W2 domain.
modificationsPhosphorylated at multiple sites in vivo. Phosphorylation at Ser-1185 by PRKCA induces binding to MKNK1.
Following infection by certain enteroviruses, rhinoviruses and aphthoviruses, EIF4G1 is cleaved by the viral protease 2A, or the leader protease in the case of aphthoviruses. This shuts down the capped cellular mRNA transcription.
- Information by UniProt
- DKFZp686A1451 antibody
- eIF 4 gamma 1 antibody
- eIF 4G 1 antibody
All lanes : Anti-eIF4G1 antibody (ab264233) at 0.04 µg/ml
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : HeLa whole cell lysate at 5 µg
Developed using the ECL technique.
Predicted band size: 175 kDa
Exposure time: 10 seconds
Immunohistochemical analysis of formalin-fixed, paraffin-embedded human ovarian carcinoma tissue labeling eIF4G1 with ab264233 at 1/200 dilution. Detection: DAB.
eIF4G1 was immunoprecipitated from HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate (1 mg for IP, 20% of IP loaded) with ab264233 at 3 µg/mg lysate. Western blot was performed from the immunoprecipitates using ab264233 at 1 µg/ml.
Lane 1: ab264233 IP in HeLa whole cell lysate.
Lane 2: Control IgG IP in HeLa whole cell lysate.
Detection: Chemiluminescence with an exposure time of 1 second.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab264233 has not yet been referenced specifically in any publications.